Royalty Pharma’s bitter battle to take over Elan is in the balance. Elan’s shares have soared since the bid was launched, but threaten to fall back if it fails. Lex’s Oliver Ralph and Vincent Boland discuss what is at stake in this takeover saga.
For more video content from the Financial Times, visit http://www.FT.com/video
